Metformin inhibits growth of lung adenocarcinoma cells by inducing apoptosis via the mitochondria-mediated pathway

JUNLING WANG¹, QIULING GAO², DECUI WANG¹, ZHIQIANG WANG¹ and CHUN HU³

¹Department of Medical Oncology, Binzhou Tuberculosis Control Center, Binzhou Medical College; ²Department of Radiology, Binzhou People's Hospital, Binzhou, Shandong 250000; ³Department of Oncology, RuiJin Hospital, Shanghai JiaoTong University, Shanghai 200001, P.R. China

Received May 20, 2014; Accepted January 29, 2015

DOI: 10.3892/ol.2015.3450

Abstract. Metformin is commonly used to treat type II diabetes, although it may also reduce the risk of cancer and improve the associated prognosis. However, its mode of action in cancer remains unclear. The present study evaluated the effects of metformin on lung adenocarcinoma A549 cells and identified molecular mechanisms of metformin activity. The A549 cells were treated with metformin at different concentrations and cell viability was assayed by using an MTT assay. The cell cycle and the apoptosis rate were assayed by flow cytometry. Nude mice were transplanted with A549 cells and the tumor growth inhibition rate was detected. Once the A549 cells had been treated with 20 mM metformin for 48 h, the cell cycle was arrested in the G0/G1 phase and the apoptosis rate was 20.57±3.16%. The expression of the B-cell lymphoma (Bcl)-2 and Bcl-extra large proteins was downregulated following metformin treatment, while Bax protein expression was significantly increased. Tumor size in the high-dose metformin and cisplatin plus metformin groups was significantly smaller, and the inhibition rates were 41.3 and 72.9%, respectively, compared with the control group. These results indicated that metformin displays anticancer activity against lung adenocarcinoma by causing G1 arrest of the cell cycle and subsequent cell apoptosis through the mitochondria-dependent pathway in A549 cells. Furthermore, it was found that metformin dramatically inhibited lung adenocarcinoma tumor growth in vivo. These data suggest that metformin may become a potential cytotoxic drug in the prevention and treatment of lung adenocarcinoma.

Introduction

Lung adenocarcinoma is one of the main causes of cancer-related mortality globally, accounting for nearly 30% of cancer-related mortalities worldwide (1). The incidence of lung adenocarcinoma is rising all over the world due to the adoption of lifestyle choices that have an association with cancer, including physical inactivity and smoking. Although advances have been made with regard to early diagnosis and treatment modalities, the prognosis for affected patients remains poor, with a five-year survival rate of only ~15% (2). As a consequence, the prevention of lung cancer is a high priority and urgent efforts are required to identify measures, including drug treatment, which may effectively reduce the risk of lung cancer. Chemotherapy is one of the best approaches for unresectable tumors, but the efficacy of current lung tumor chemotherapy is only modest and the requirement for an optimal lung adenocarcinoma treatment remains. Metformin, a biguanide drug, has been demonstrated to exert anticancer effects (3). The drug reduces the level of glucose by decreasing liver glucose production, thereby increasing fatty acid oxidation and glucose utilization. Notably, previous epidemiological studies suggested that patients with diabetes who were treated with metformin had a lower cancer-related mortality rate and a lower incidence rate of cancer of any type when compared with patients who underwent other treatments (4-7). Additionally, metformin was shown to prevent the induction of carcinogen-induced pancreatic cancer in hamsters that were maintained on high-fat diets (8). The drug was also shown to inhibit the growth of breast and colon carcinoma cells (9,10). Collated evidence from a number of clinical studies has recently been published in a meta-analysis (11). However, the precise mechanisms involved remain incompletely understood. The antitumor activity of metformin may be explained by two mechanisms. Firstly, metformin is able to decrease insulin resistance and lower the levels of circulating insulin by activating AMP-activated protein kinase (AMPK), which causes decreased hepatic gluconeogenesis (10) and increased glucose uptake in the muscle. Secondly, metformin acts as an inhibitor of tumor growth, at least in part by upregulating the activity of AMPK and by downstream suppression of signaling through the mammalian target of rapamycin (mTOR) (12). Several other
potential mechanisms for the anticancer action of metformin have also been demonstrated, including the suppression of HER2 oncoprotein expression, the downregulation of cyclin D1 expression and p53 activation (9,13-15). However, there have been few studies evaluating the potential utility of metformin in in vivo models of cancer, and the method by which metformin induces apoptosis remains unknown. The present study describes experiments that were performed to investigate the hypothesis that metformin exhibits direct anti-proliferative actions on lung adenocarcinoma cells in vitro and in vivo.

Materials and methods

Chemicals and reagents. Metformin was obtained from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in phosphate-buffered saline (PBS). Cell culture chemicals and materials were obtained from Invitrogen Life Technologies (Burlington, ON, Canada). Anti-β-actin, anti-B-cell lymphoma (Bcl)-2, anti-Bax and anti-caspase-3 were purchased from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-conjugated anti-rabbit immunoglobulin (IgG), anti-mouse IgG and enhanced chemiluminescence (ECL) reagents were obtained from Amersham Pharmacia Biotech (Piscataway, NJ, USA).

Cell lines and culture conditions. The human lung adenocarcinoma A549 cells were obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). The A549 cells were maintained in Dulbecco’s modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mmol/L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C, in an atmosphere of 5% CO2. The cells were passaged by 0.25% Trypsin-EDTA when they reached 80% confluence.

Cell proliferation assay. An MTT assay was used to evaluate the effect of metformin on the lung adenocarcinoma cells. Briefly, ~10,000 cells were seeded into 96-well tissue culture plates and then treated with different doses (0, 5, 10, 20 and 50 mM) of metformin for 24, 48 and 72 h, respectively. MTT reagent was then added to each well, and the cells were further incubated for 6 h. Absorbance was measured in an automated microplate reader (ELX 800; BioTek Instruments, Inc., Winooski, VT, USA) at 450 nm.

Cell morphological analysis. The A549 cells were treated with 10.0 mM metformin or 0.1% dimethyl sulfoxide (control) for 48 h. The cells were then incubated with 10 µg/ml Hoechst 33342 and observed by fluorescence microscope (DMIRE; Leica, Wetzler, Germany).

Flow cytometry. The A549 cells were starved of serum for 24 h and then treated with different doses (0, 10 and 20 mM) of metformin for 48 h. The cells were then washed with PBS (pH 7.4) and fixed with 70% ice-cold ethanol at 4°C overnight. After fixation, the cells were stained with propidium iodide (PI) at 1 mg/ml for 30 min at room temperature. The cell cycle was analyzed by flow cytometry (FACScan; BD Biosciences, Franklin Lakes, NJ, USA).

For cell apoptosis detection, the apoptotic rate of A549 cells was analyzed using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). A total of 1x10^5 cells/well were seeded into six-well plates and cultured in DMEM at 37°C overnight. Subsequent to starvation for 12 h, the cells were treated with different doses of metformin (0, 10 and 20 mM) in complete medium for 48 h, digested with 2.5 mg/ml trypsin, washed twice with PBS and suspended with 300 µl binding buffer (Nanjing KeyGen Biotech Co., Ltd.). The cells were then incubated with 2 µl Annexin V and 5 µl PI for 15 min at room temperature, and the distribution of viable, early apoptotic, late apoptotic and necrotic cells was detected using a FACSCaliber flow cytometer (BD Biosciences). Cells that were negative for the Annexin V-FITC and PI were considered to be viable cells, cells that were positive for Annexin V-FITC, but negative for PI were considered to be early apoptotic cells, cells that were positive for Annexin V-FITC and PI were considered to be late apoptotic cells, while cells that were negative for both Annexin V-FITC and PI were considered to be necrotic. The sum of the early and late apoptotic cells constituted the total number of apoptotic cells, which was presented as the percentage of the total cells.

Mitochondrial and cytosolic fractionation. The Cell Mitochondria Isolation kit (Beyotime Institute of Biotechnology, Haimen, China) was used to perform the isolation of the mitochondria and cytosol, according to the manufacturer's instructions. Samples of cytosol and mitochondria were dissolved in lysis buffer, and proteins were subjected to western blotting, respectively.

Western blot analysis. The A549 cells were lysed in a radioimmunoprecipitation assay buffer (9.1 mM dibasic sodium phosphate, 1.7 mM monobasic sodium phosphate, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.2 mM sodium vanadate, 0.2 mM phenylmethylsulfonyl fluoride and 0.2 U/ml aprotinin). Clarified protein lysates (50 g) were resolved electrophoretically on denaturing SDS-polyacrylamide gels (10%), and transferred to nitrocellulose membranes. The membranes were then blocked with 5% bovine serum albumin at room temperature for 1 h and then incubated with the indicated specific primary antibodies for 3 h. Proteins were visualized with Horseradish peroxidase (HRP)-conjugated secondary antibodies. To corroborate equal loading, membranes were stripped and reprobed using an antibody specific for β-actin. Finally, antigen-antibody complexes were detected using the ECL system.

A549 tumor xenograft. A total of 6x10^6 A549 cells were injected into the right flank of 30 BALB/c nude mice (supplied by the Experimental Animal Department of Binzhou medical College, Shandong, China). Seven days later, 25 mice with tumors ~100 mm^3 in size were randomly distributed into the following five groups: Control group (PBS), low-dose metformin (40 mg/kg/day) group, high-dose metformin (200 mg/kg/day) group, cisplatin (5 mg/kg/day) group and metformin (40 mg/kg/day) plus cisplatin (5 mg/kg/day) group. Tumor volume (mean values and 95% confidence intervals) was measured every three days after the initial injection. After
18 days, the mice were sacrificed by cervical dislocation and the tumor weights were measured. The study was approved by the ethics committee of Binzhou Medical College (Binzhou, China).

Statistical analysis. All experiments, except that of the nude mice study, were repeated at least three times and the values are expressed as the mean ± standard deviation. Statistical significance was determined by Student's t-test. *P<0.05 was considered to indicate a statistically significant difference.

Results

**Metformin inhibits human lung carcinoma A549 survival in a dose- and time-dependent manner.** The viabilities of A549 cells treated with different concentrations of metformin (0, 5, 10, 20 and 50 mmol/l) for different time periods (0, 24, 48 and 72 h) were determined using MTT assay. As shown in Fig. 1A, the cell viabilities were decreased in a dose- and time-dependent manner. Cisplatin is the most active treatment for lung carcinoma, however, the sensitivity of tumor cells to cisplatin varies. The present results indicated that metformin could increase the cytotoxicity of cisplatin in A549 cells (Fig. 1B).

**Metformin induces cell cycle arrest in the G0/G1 phase in human lung adenocarcinoma cells.** To identify the effect of metformin on the cell cycle of human lung carcinoma cells, the cell cycle distribution of A549 cells treated with different concentrations of metformin (0, 10 and 20 mmol/l) for 48 h...
was determined using a PI staining assay. As shown in Fig. 2, metformin induced cell cycle arrest in the G<sub>0</sub>/G<sub>1</sub> phase in the A549 cells. Treatment with different doses of metformin (10 or 20 mM) for 48 h resulted in an increase in A549 cells in the G<sub>0</sub>/G<sub>1</sub> population, to 65.9 and 82.6%, respectively, compared with 54.6% in the untreated control group (Fig. 2).

Metformin induces apoptosis in human lung adenocarcinoma cells. Hoechst-33342 and Annexin-V/PI staining assays were combined to investigate whether metformin can induce A549 cell apoptosis. First, the apoptotic morphology of the A549 cells treated with 10.0 mM metformin for 24 h was observed, and the metformin-treated cells were shown to manifest brighter, granular, blue fluorescence and more apoptotic bodies compared with control group (Fig. 3A). The percentage of apoptotic cells was determined by cell flow cytometric analysis following PI staining. Compared with the untreated cells, the cells treated with metformin for 48 h underwent apoptosis in a dose-dependent manner (Fig. 3B).

**Metformin induces apoptosis mainly through the mitochondria-mediated pathway.** The treatment with metformin decreased the expression of Bcl-2 and Bcl-extra large (Bcl-xl), and increased the expression of Bax in a dose-dependent manner in the A549 cells, as determined by western blot analysis (Fig. 4A). Downstream of the apoptosis signaling pathways, there is significant cleavage activation of caspase-3 and poly(ADP-ribose) polymerase (PARP) (Fig. 4B). A significant release of cytochrome c from the mitochondria to the cytosol was observed after the cells were treated with metformin (Fig. 4C). These results indicate that metformin induces apoptosis mainly through the mitochondria-mediated internal pathway in lung carcinoma cells.

**Metformin suppresses tumor proliferation in vivo.** In order to determine whether metformin could affect tumor growth, the effect of metformin on tumor growth inhibition was studied in vivo via intraperitoneal injection. It was found that tumor growth was markedly inhibited in the high-dose metformin
and metformin plus cisplatin groups (Fig. 5A). Compared with the control group, the tumor xenograft treated with metformin (200 mg/kg/day) was significantly decreased in size (Fig. 5B). In addition, there was a significant decrease in tumor size in the metformin (40 mg/kg/day) plus cisplatin group, when compared with the other groups (Fig. 5C). The tumor volume
of the high-dose metformin and metformin plus cisplatin groups was 61.4±51.5 and 281.6±21.1 mm³, respectively, compared with the control group (1,042.4±397.7 mm³). The tumor growth inhibition rate was 41.3% in the high-dose metformin group (P<0.01) and 72.9% in the metformin plus cisplatin group (P<0.01) compared with the control (Fig. SD). Body weight reduction is an indicator of drug toxicity. In the high-dose metformin and metformin plus cisplatin groups, body weight was 22.31±1.69 and 23.83±2.39 g, respectively (Fig. 5E), which was comparable to the control group.

Discussion

Metformin has a long history of human use, with less toxicity and a relatively low cost when compared with other anti-diabetic drugs. The drug is now widely used as a first-line treatment for type II diabetes (16). Notably, numerous studies have indicated that metformin could protect patients with type II diabetes from cancer and inhibit cancer cell proliferation in vitro (17-22). According to the present study, metformin is a potent inhibitor of cell proliferation in the A549 cell line. For example, inhibition of cell proliferation was observed in the A549 cells treated with 20 mM metformin for 48 h, with a 63% decrease in cell viability. The study then analyzed whether metformin affects the cell cycle. To determine this, proliferating A549 cells were treated with metformin for 48 h at different concentrations. As shown in Fig. 2, an increasing number of cells accumulated in the G1/G0 phase. In parallel, a reduced percentage of cells was observed in the S and G2/M phases. In order to determine whether metformin induces apoptosis in A549 cells, an Annexin V-fluorescein isothiocyanate labeling assay and found that metformin at concentrations of <5 mM did not affect the amount of Annexin V-positive cells (data not shown). However, metformin at a concentration of >5 mM increased the percentage of cells positive for Annexin V. These results indicate that metformin can induce apoptosis, but only at high concentrations.

There are two classic apoptotic pathways in mammalian cells, namely the mitochondria-mediated apoptotic pathway and the death receptor-mediated apoptotic pathway, and there is cross-talk between the two. To further clarify the apoptotic molecular mechanisms of human lung carcinoma cells induced by metformin, the total proteins of the A549 cells treated with different concentrations of metformin for 24 h were analyzed using a western blot assay. Using the present data, it may be concluded that metformin induces the apoptosis of A549 cells in vitro mainly via the mitochondria-mediated internal pathway, which is initiated by a range of apoptosis-inducing signals that cause an imbalance in the major apoptosis regulators, the proteins of the Bcl-2 family, such as Bcl-2, Bcl-xL and Bax. Bax, a pro-apoptotic protein, accumulates on the mitochondria subsequent to being activated, and triggers the permeability of the outer mitochondrial membrane to increase. As a result, the mitochondria release cytochrome c. This, in turn, activates downstream death programs, such as caspase 3 and PARP. These observations suggested that modulation of the mitochondria-mediated pathway may be an important mechanism underlying the biological effects of metformin. The present study results are similar to those in the study by Gotlieb et al (23), which reported that metformin significantly inhibits the ovarian cancer cell line growth and potentiates the effects of cisplatin. Additionally, the inhibition of growth by metformin was partially abolished by the AMPK inhibitor, compound C. The study also discovered that metformin-induced anti-proliferation is associated with the phosphorylation of AMPK and the decrease of p-p70S6K (23). Another study found that metformin was able to induce apoptosis in vitro in colon cancer cells, but only in those cells that were p53-deficient (9). A subsequent study found that metformin in combination with paclitaxel resulted in mainly G1 arrest and decreased human telomerase reverse transcriptase mRNA expression. Metformin was demonstrated to potentiate the effects of paclitaxel in endometrial cancer cells by inhibiting cell proliferation and modulating the mTOR pathway (24). In another study, metformin was found to decrease high-fat-induced cardiac cell death by inhibiting ceramide synthesis. However, proton and lactate accumulation are induced by metformin, which leads to caspase-3-independent cell damage at high concentrations (25). These studies indicate that metformin mediates its effects through a range of mechanisms.

In vivo, the present data showed that the high-dose metformin and metformin plus cisplatin groups could significantly decrease A549 tumor growth without any significant side-effects, including weight loss, hair loss, dysphoria or lethargy. The present results are of particular significance since this is the first time that metformin has been shown to inhibit lung adenocarcinoma growth in a xenograft model. Similar to the present study, a study by Huang et al reported that metformin delayed the onset of tumors, but in mice deficient in the phosphatase and tensin homolog tumor suppressor (26). Ben Sahra et al found that metformin inhibited prostatic tumor growth in vivo (27). Another study also found that metformin could prevent pancreatic cancer in hamsters fed a high-fat diet and exposed to pancreatic carcinoma (8).

Thus, in summary, the present study is a preliminary study suggesting that metformin selectively induces the apoptosis of lung carcinoma A549 cells via the mitochondria-mediated internal pathway. Although metformin has been demonstrated to inhibit proliferation in vitro in prostate, breast, colon and ovarian cancer cell lines, the present study observed its effect on lung adenocarcinoma for the first time. The results support the development of pre-clinical experiments to further evaluate the potential role of combining metformin with chemotherapy as a new treatment for lung adenocarcinoma. Further long-term studies of metformin are required in patient populations of similar and larger sizes in order to confirm these observations.

Acknowledgements

This study was supported by a grant from the National Science and Technology Special Foundation for Major Infectious Diseases Prevention and Control (No. 2008Ex 10002019).

References